Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inolimomab - ElsaLys Biotech/Jazz Pharmaceuticals

Drug Profile

Inolimomab - ElsaLys Biotech/Jazz Pharmaceuticals

Alternative Names: Anti-CD25 monoclonal antibody B-B10; Anti-interleukin-2 receptor monoclonal antibody B-B10; B-B10; BT-563; Leukotac

Latest Information Update: 08 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OPi
  • Developer ElsaLys Biotech
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Graft-versus-host disease

Most Recent Events

  • 08 Aug 2019 Inolimomab is still in phase III trial for Graft-versus-host disease in Belgium and France (IV)
  • 08 Aug 2019 ElsaLys Biotech announces intention to submit MAA to EMA for Graft-versus-host disease in 2019 (ElsaLys Biotech website, August 2019)
  • 08 Aug 2019 ElsaLys Biotech announces intention to submit NDR to FDA for Graft-versus-host disease in 2020 (ElsaLys Biotech website, August 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top